Organophosphorus pesticide chlorpyrifos intake promotes obesity and insulin resistance through impacting gut and gut microbiota (Microbiome 2019, 7:19)

報告日期: 2020/12/08
報告時間: 15:10/16:00
報告學生: 池佩姍
講評老師: 阮振維
附件下載:

Organophosphorus pesticide chlorpyrifos intake promotes obesity and insulin resistance through impacting gut and gut microbiota

Yiran Liang, Jing Zhan, Donghui Liu, Mai Luo, Jiajun Han, Xueke Liu, Chang Liu, Zheng Cheng, Zhiqiang Zhou & Peng Wang

Microbiome 7, 19 (2019)

Speaker: Pei-Shan Chih                                           Time: 15:10-16:00, Dec. 8th, 2020

Commentator: prof. Jhen-Wei Ruan                        Place: Room 602

Abstract

With economic development and changes in eating habits, the prevalence of obesity in the world had increased in the last decades. Current epidemiological researches have indicated that obesity was not only related to excessive fat accumulation but also low-grade inflammation, and may increase the risk of chronic diseases, such as type 2 diabetes and cardiovascular disease. In recent studies, it has found that disruption of the gut microbiota homeostasis may induce low-grade inflammation leading to obesity-associated diseases. Chlorpyrifos, one of the most widely used long-term exposure to organophosphorus pesticides, had been reported to cause disease in multiple organs, such as the pancreas, liver and endocrine system, etc. To investigate whether pesticides would induce insulin resistance/obesity through interfering with gut microbiota homeostasis, this study conducted a study to determine how long-term effects of exposure to chlorpyrifos in C57Bl/6 and CD-1 (ICR) mice which fed high-fat or normal-fat diets. Further, to investigate the change of microbiota, antibiotic treatment, and microbiota transplantation experiments were conducted. The results showed that chlorpyrifos caused broken integrity of the gut barrier, leading to increased lipopolysaccharide entry into the body and finally induced low-grade inflammation. Genetic background and diet pattern have limited influence on the chlorpyrifos-induced results. Moreover, the results of antibiotic treatment and microbiota transplantation all showed that chlorpyrifos-altered microbiota was involved in chlorpyrifos-induced insulin resistance and obesity.

Reference

  1. Thaiss, C., et al. The microbiome and innate immunity. Nature 535, 65–74 (2016).
  2. Lin, Tzu-Lung, et al. Like cures like: pharmacological activity of anti-inflammatory lipopolysaccharides from gut microbiome. Frontiers in Pharmacology 11 (2020).